Product Images Xarelto
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 13 images provide visual information about the product associated with Xarelto NDC 50090-3639 by A-s Medication Solutions, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Label Image - lbl500903639
Figure 1 - xarelto 01
This appears to be a statistical chart showing various comparisons between the drugs rivoxaban and warfarin. The chart details hazard ratios and confidence intervals for both drugs in relation to several variables such as age, gender, weight, and more.*
Figure 2 - xarelto 02
The text seems to be a table with various factors including age, sex, weight, region, medical history, and bleeding risk being analyzed for their impact on bleeding incidence in individuals taking XARELTO plus aspirin compared to taking aspirin alone. It is not clear what the values in the table represent without further context.*
Chemical Structure - xarelto 03
Figure 3 - xarelto 04
This text contains pharmacokinetic data for different subpopulations based on certain clinical characteristics. The text reports the fold change and 90% confidence interval in PK parameters such as AUC and Cmax for the subpopulations defined by End-Stage Renal Disease, Renal Impairment, Age, Body Weight, and Hepatic Impairment. The PK parameters were assessed for different subpopulations based on normal values and the relative change in these parameters is presented. The text also includes a note on the reference population and the dosage of the drug administered.*
Figure 4 - xarelto 05
This is a table showing the fold change in pharmacokinetics and 90 percent confidence intervals of various drugs when taken in combination with different inhibitors or inducers. The drugs include aspirin, atorvastatin, clarithromycin, clopidogrel, digoxin, enoxaparin, erythromycin, fluconazole, ketoconazole, midazolam, naproxen, omeprazole, ranitidine, and rifampicin. The inhibitors and inducers include strong and moderate inhibitors of the CYP3A enzyme and P-glycoprotein. The table also shows the change in pharmacokinetics relative to rivaroxaban alone.*
Figure 5 - xarelto 06
The text describes a chart showing Cumulative Event Rates (%) for XARELTO and Warfarin along with HR (95% CI) and the number of subjects at risk. The chart also displays the days from Randommization. However, the data in the chart is not useful as the values are not clearly mentioned.*
Figure 6 - xarelto 07
Figure 7 - xarelto 08
The text provided seems to be a graph or chart, showing cumulative event rates over time for various treatments. It is not possible to generate a useful description with this text.*
Figure 8 - xarelto 09
Figure 9 - xarelto 10
Figure 10 - xarelto 11
Figure 11 - xarelto 12
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.